ClinicalTrials.gg

Program

dabogratinib

Also written as “Dabogratinib (TYRA-300) 60mg”, “Dabogratinib (TYRA-300) 80mg” and “TYRA-300 60mg”.

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Achondroplasia · Carcinoma, Transitional Cell, led by Tyra Biosciences.

Furthest: phase 2, since Sep 6, 20225 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tyra Biosciences55 open or runningphase 2since Sep 6, 2022Sep 6, 2022Nov 2026phase 2 · NCT05544552

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 6, 2022First study: phase 2 study in Carcinoma, Transitional CellFirst studyNCT05544552 · 310 enrolled · United States, Australia, France and more
  2. Aug 17, 2023Phase 1 study in HealthyNCT06006702 · 60 enrolled · Australia
  3. Jan 29, 2025Phase 2 study in AchondroplasiaNCT06842355 · 92 planned · United States, Australia, Canada and more
  4. Apr 25, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06995677 · 90 planned · United States, Australia, Italy and more
  5. Nov 19, 2025Phase 2 study in Low Grade Upper Tract Urothelial CarcinomaNCT07265947 · 285 planned · United States, France, Israel and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Carcinoma, Transitional CellNCT05544552
  2. Feb 2028Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06995677
  3. Jan 2030Primary completion: phase 2 study in AchondroplasiaNCT06842355
  4. Oct 2030Primary completion: phase 2 study in Low Grade Upper Tract Urothelial CarcinomaNCT07265947

TargetBeta

FGFR3 →read by rule
“An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 3 (FGFR3), ”NCIt, by rule

Other programs on FGFR3

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
masitinibruleAB Sciencephase 338
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
vepugratinibruleEli Lillyphase 35
FGFR3/4 Inhibitor TYRA-430ruleTyra Biosciencesphase 11
Anti-FGFR3 Antibody-drug Conjugate BHV-1530rulebiohaven-therapeutics-ltdphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07265947Low Grade Upper Tract Urothelial Carcinoma · United States, France, Israel and more2RecruitingOct 2030285
NCT06995677Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Italy and more2RecruitingFeb 202890
NCT06842355Achondroplasia · United States, Australia, Canada and more2RecruitingJan 203092
NCT06006702Healthy · Australia1Active, not recruitingMay 202560
NCT05544552Carcinoma, Transitional Cell · United States, Australia, France and more2Active, not recruitingNov 2026310

How it is read

Names in the registry

  • “Dabogratinib (TYRA-300) 60mg”, 1 entry
  • “Dabogratinib (TYRA-300) 80mg”, 1 entry
  • “TYRA-300 60mg”, 1 entry
  • “TYRA-300 50mg”, 1 entry
  • “TYRA-300 Dose 70 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.